3,168
Views
1
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

, , , , , & show all
Pages 1124-1133 | Received 15 Sep 2020, Accepted 27 Aug 2021, Published online: 30 Sep 2021